Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Tri-Institutional Therapeutics Discovery Institute, Inc. currently manages 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner, BAUER, NICOLA MARIA. As the busiest examiner for the portfolio, BAUER, NICOLA MARIA is responsible for 1 pending office action, which constitutes the total active workload for the applicant at this time.
The prosecution is localized in 1 distinct art unit, suggesting that the subject matter falls within a specific technical niche. The involvement of only 1 distinct art unit means that the company does not currently have a diversified set of active matters across different specialized groups. This concentration of the pending matter under the assigned examiner indicates a very focused prosecution effort.
For Tri-Institutional Therapeutics Discovery Institute, Inc., the success of their current patenting activity depends on the review within this Biotechnology & Pharmaceuticals sector. Since the company has a single active case, it can concentrate its resources on the specific requirements of the assigned staff. The 1 distinct art unit provides a singular administrative context for the resolution of the company's active matter.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BAUER, NICOLA MARIA | 1 | 58.3% | +50.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18288368 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | BAUER, NICOLA MARIA | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18288368 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | BAUER, NICOLA MARIA | 1621 | §103 | Non-Final OA | — | Pending | Oct 25, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial